Ivosidenib - Agios Pharmaceuticals

Drug Profile

Ivosidenib - Agios Pharmaceuticals

Alternative Names: AG-120

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Agios Pharmaceuticals
  • Developer AbbVie; Agios Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cyclobutanes; Nitriles; Pyridines; Pyrrolidines; Small molecules
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Acute myeloid leukaemia
  • Phase III Cholangiocarcinoma
  • Phase I Glioma; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 19 Mar 2018 Phase-I/II clinical trials in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT03471260)
  • 19 Mar 2018 M.D. Anderson Cancer Center initiates a phase-I/II clinical trials in Acute myeloid leukaemia (Combination therapy, First-line therapy) in USA (PO) (NCT03471260)
  • 15 Feb 2018 FDA assigns PDUFA action date of 21/08/2018 for ivosidenib for Acute myeloid leukaemia (Second-line therapy or greater)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top